A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Trial Profile

A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT P3
  • Sponsors Eli Lilly
  • Most Recent Events

    • 16 Jun 2018 Results assessing the safety of Ixekizumab in patients with active Psoriatic Arthritis using data pooled from 3 (SPIRIT-P1, -P2, and -P3) Phase 3 trials presented at the 19th Annual Congress of the European League Against Rheumatism
    • 06 Jun 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
    • 26 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top